https://www.selleckchem.com/pr....oducts/zinc05007751.
Antibodies against the HPV16 oncoprotein E6 are promising biomarkers for HPV16-driven oropharyngeal cancer (HPV16-OPC) due to their high sensitivity and specificity, and prospective manifestation. In previous studies, 0•7% of controls without HPV-associated malignancies were HPV16 E6 seropositive of which only a minority is expected to develop HPV16-driven cancer. We aimed to characterise HPV16 E6 antibodies in individuals without HPV-associated malignancies. We analysed serum antibodies against HPV16 E6, E7, L1 and HPV18 L1 in a r
Like
Comment
Share
